黑色素-话题@MedSci

#黑色素#

1110篇内容 | 1871人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1559084, encodeId=743115590841f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析, objectType=article, longId=215870, objectId=7c302158e0f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c302158e0f8, replyNumber=0, likeNumber=80, createdTime=2021-08-18, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c302158e0f8, moduleTitle=Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c302158e0f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565093, encodeId=129915650938c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析, objectType=article, longId=215870, objectId=7c302158e0f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c302158e0f8, replyNumber=0, likeNumber=90, createdTime=2021-08-18, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c302158e0f8, moduleTitle=Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c302158e0f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559083, encodeId=c56c155908382, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, objectType=article, longId=215840, objectId=dfc62158401b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc62158401b, replyNumber=0, likeNumber=65, createdTime=2021-08-18, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc62158401b, moduleTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc62158401b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565092, encodeId=f407156509226, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, objectType=article, longId=215840, objectId=dfc62158401b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc62158401b, replyNumber=0, likeNumber=65, createdTime=2021-08-18, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc62158401b, moduleTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc62158401b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565091, encodeId=18951565091c4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：早早使用大剂量激素管理irAE与抗PD-1单药治疗晚期黑色素瘤的预后不良相关, objectType=article, longId=215687, objectId=dd9b21568e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd9b21568e2a, replyNumber=0, likeNumber=64, createdTime=2021-08-14, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd9b21568e2a, moduleTitle=Clin Cancer Res：早早使用大剂量激素管理irAE与抗PD-1单药治疗晚期黑色素瘤的预后不良相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd9b21568e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559082, encodeId=e88d15590823b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：早早使用大剂量激素管理irAE与抗PD-1单药治疗晚期黑色素瘤的预后不良相关, objectType=article, longId=215687, objectId=dd9b21568e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd9b21568e2a, replyNumber=0, likeNumber=65, createdTime=2021-08-14, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd9b21568e2a, moduleTitle=Clin Cancer Res：早早使用大剂量激素管理irAE与抗PD-1单药治疗晚期黑色素瘤的预后不良相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd9b21568e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565090, encodeId=0920156509034, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力, objectType=article, longId=215634, objectId=2166215634d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2166215634d4, replyNumber=0, likeNumber=0, createdTime=2021-08-14, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2166215634d4, moduleTitle=INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2166215634d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559081, encodeId=f7f115590817a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力, objectType=article, longId=215634, objectId=2166215634d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2166215634d4, replyNumber=0, likeNumber=83, createdTime=2021-08-14, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2166215634d4, moduleTitle=INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2166215634d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565089, encodeId=81a1156508967, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, objectType=article, longId=215390, objectId=5ac7215390be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ac7215390be, replyNumber=0, likeNumber=63, createdTime=2021-08-08, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ac7215390be, moduleTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ac7215390be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559080, encodeId=97371559080f1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, objectType=article, longId=215390, objectId=5ac7215390be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ac7215390be, replyNumber=0, likeNumber=69, createdTime=2021-08-08, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ac7215390be, moduleTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ac7215390be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559079, encodeId=3e1415590e9a4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关, objectType=article, longId=215275, objectId=07ce2152e534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ce2152e534, replyNumber=0, likeNumber=57, createdTime=2021-08-05, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ce2152e534, moduleTitle=Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ce2152e534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565088, encodeId=63fe156508815, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关, objectType=article, longId=215275, objectId=07ce2152e534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ce2152e534, replyNumber=0, likeNumber=64, createdTime=2021-08-05, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ce2152e534, moduleTitle=Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ce2152e534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565087, encodeId=84bf156508e9d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, objectType=article, longId=215238, objectId=cb2d215238b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d215238b4, replyNumber=0, likeNumber=55, createdTime=2021-08-05, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d215238b4, moduleTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d215238b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559078, encodeId=b1db15590e8bf, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, objectType=article, longId=215238, objectId=cb2d215238b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d215238b4, replyNumber=0, likeNumber=72, createdTime=2021-08-05, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d215238b4, moduleTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d215238b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565086, encodeId=4b9515650864b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存, objectType=article, longId=214994, objectId=c253214994bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c253214994bf, replyNumber=0, likeNumber=92, createdTime=2021-07-30, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c253214994bf, moduleTitle=JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c253214994bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559077, encodeId=94cd15590e76d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存, objectType=article, longId=214994, objectId=c253214994bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c253214994bf, replyNumber=0, likeNumber=101, createdTime=2021-07-30, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c253214994bf, moduleTitle=JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c253214994bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559076, encodeId=8c8a15590e625, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=72, createdTime=2021-07-24, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565085, encodeId=b6921565085cc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=68, createdTime=2021-07-24, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559075, encodeId=e16c15590e572, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, objectType=article, longId=214405, objectId=fc05214405fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc05214405fd, replyNumber=0, likeNumber=85, createdTime=2021-07-20, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc05214405fd, moduleTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc05214405fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565084, encodeId=3e0d1565084f0, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, objectType=article, longId=214405, objectId=fc05214405fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc05214405fd, replyNumber=0, likeNumber=83, createdTime=2021-07-20, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc05214405fd, moduleTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc05214405fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

黑色素

2020-05-29

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析

2021-08-18

hb2008ye (审核中...)

前往app查看评论内容

#黑色素#

Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析

2021-08-18

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后

2021-08-18

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后

2021-08-18

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：早早使用大剂量激素管理irAE与抗PD-1单药治疗晚期黑色素瘤的预后不良相关

2021-08-14

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：早早使用大剂量激素管理irAE与抗PD-1单药治疗晚期黑色素瘤的预后不良相关

2021-08-14

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力

2021-08-14

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力

2021-08-14

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药

2021-08-08

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药

2021-08-08

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关

2021-08-05

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关

2021-08-05

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答

2021-08-05

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答

2021-08-05

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存

2021-07-30

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存

2021-07-30

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2021-07-24

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2021-07-24

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效

2021-07-20

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效

2021-07-20

科室
- - 订阅+
  - 更多科室
工具
服务